Company Overview#
AAVATAR Therapeutics is an AI-driven AAV capsid engineering company developing next-generation gene delivery platforms for rare and intractable diseases. The company combines a machine learning-based capsid engineering platform with in-house AAV manufacturing capabilities to enable rapid design, production, and validation of tissue-targeted AAV vectors. AAVATAR is positioned as a platform company focused on capsid licensing and co-development with pharmaceutical partners.
Technology & Product#
AAVATAR’s core technology is a machine learning-driven AAV capsid engineering platform that prioritizes manufacturability while identifying high-performing tissue-targeted capsids. Large-scale capsid libraries are screened using next-generation sequencing and iteratively optimized through rodent and non-human primate validation. The platform is integrated with in-house AAV manufacturing capabilities covering vector design, process optimization, quality control, and scalable nonclinical production, enabling rapid discovery and validation of licensing-ready AAV capsid assets.
Market & Use Cases#
AAVATAR develops AI-engineered AAV capsid platforms for tissue-specific in vivo gene delivery. The current strategic focus is on CNS, heart, skeletal muscle, and kidney targeting. Proof-of-platform programs include Krabbe disease, hereditary hearing loss, and geographic atrophy (GA). Beyond these indications, the platform can be rapidly adapted to additional tissues such as the PNS and pancreas according to partner needs. The company’s business model is centered on capsid platform licensing and co-development with pharmaceutical partners.
Traction & References#
AAVATAR raised a KRW 5 billion Series A in late 2023, led by TS Investment with Shinhan Capital, Smilegate Investment, and Wonik Investment Partners joining(BioSpectator). It was selected as a government Baby Unicorn company in 2024(AAVATAR). AAVATAR runs research collaborations with academic and medical partners including Ewha Womans University, Yonsei University, Seoul National University, and Samsung Medical Center(AAVATAR).
Collaboration Relevance#
AAVATAR is well positioned for collaborations with pharmaceutical companies and academic institutions through joint validation, MTAs, sponsored research, co-development, and platform licensing. The company is currently advancing CNS, heart, skeletal muscle, and kidney targeting programs while maintaining a flexible platform that can be adapted to additional tissues and therapeutic indications based on partner needs.